JPRN-jRCTs051210205
Recruiting
Phase 1
Development of a new diagnostic method for pancreatic cancer using 13C-labeled glucose-derived metabolites: a single-arm, exploratory clinical study
Tobimatsu Kazutoshi0 sites60 target enrollmentMarch 25, 2022
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Pancreatic cancer, benign pancreatic diseases, or other gastroenterological cancers
- Sponsor
- Tobimatsu Kazutoshi
- Enrollment
- 60
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age over 20, under 80
- •2\. Diagnosed patients of pancreatic cancer, benigh pancreatic disease or other gastroenterological cancer
- •3\. Patients who have given their free and written consent to participate in this clinical research.
Exclusion Criteria
- •1\. ECOG\-PS 4, or patients who have difficulty urinating or collecting urine on their own
- •2\. Patients deemed inappropriate by the attending doctor
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Developing a diagnostic method for pancreatic cancer at the very early stageIntraductal papillary mucinous neoplasm (IPMN), Pancreatic cancerJPRN-UMIN000017958Osaka City University100
Completed
Not Applicable
Innovation of new diagnostic modalities for pancreatic cancer using PET-MRIpancreatic cancerJPRN-UMIN000016679Fukushima Medical University30
Recruiting
Not Applicable
Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in UrinePancreas CancerDiagnosisNCT06291779Ho-Seong Han120
Recruiting
Not Applicable
Project for detection of pancreatic cancer at an early stage with curative surgery in Osaka cityJPRN-UMIN000026915Tazuke Kofukai Medical Research Institute, Kitano Hospital400
Completed
Not Applicable
Development of cytological analysis of pancreatic cancer using homology technologypancreatic cancerJPRN-UMIN000044462Mie University180